Publication
Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (8)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 8
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- cancerMalignant Lung Neoplasmcivic_curation1.00
- drugErlotinibcivic_curation1.00
- drugTeprotumumabcivic_curation1.00
- geneEGFRcivic_curation1.00
- geneKRAScivic_curation1.00
- variantEGFR Mutationcivic_curation1.00
- variantKRAS Mutationcivic_curation1.00
Curated evidence
Evidence citing this paper (3)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22025157
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KRAS Mutation2 | ||||||||
| Erlotinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Resistance | 2 | accepted | EID2242In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib and placebo, patients whose tumors harbored KRAS mutations (n=8) had a lower 12-week progression-free survival… (full text at CIViC) PMID 22025157 · Ramalingam et al., 2011 · Open in CIViC | civic |
| Erlotinib + TeprotumumabCombination | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID3713In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib daily and teprotumumab (R1507) weekly or every three weeks, patients whose tumors harbored KRAS mutations had … (full text at CIViC) PMID 22025157 · Ramalingam et al., 2011 · Open in CIViC | civic |
| EGFR Mutation1 | ||||||||
| Erlotinib | Malignant Lung Neoplasm | Predictive | B | Supports Sensitivity Response | 2 | accepted | EID3864In advanced-stage (IIIB or IV) non-small cell lung cancer patients treated with erlotinib, patients whose tumors harbored EGFR mutations (n=3) had a higher 12-week progression-free survival rate compa… (full text at CIViC) PMID 22025157 · Ramalingam et al., 2011 · Open in CIViC | civic |